Burney Co. Raises Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Burney Co. boosted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 603.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 83,152 shares of the specialty pharmaceutical company's stock after acquiring an additional 71,331 shares during the period. Burney Co. owned 0.15% of Supernus Pharmaceuticals worth $3,007,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in SUPN. Commonwealth Equity Services LLC lifted its position in shares of Supernus Pharmaceuticals by 3.6% during the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company's stock worth $273,000 after acquiring an additional 350 shares in the last quarter. Texas Permanent School Fund Corp raised its stake in shares of Supernus Pharmaceuticals by 9.2% during the 2nd quarter. Texas Permanent School Fund Corp now owns 52,214 shares of the specialty pharmaceutical company's stock valued at $1,397,000 after purchasing an additional 4,400 shares during the period. American Century Companies Inc. lifted its holdings in Supernus Pharmaceuticals by 369.1% during the 2nd quarter. American Century Companies Inc. now owns 501,658 shares of the specialty pharmaceutical company's stock worth $13,419,000 after purchasing an additional 394,728 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Supernus Pharmaceuticals by 12.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,866,887 shares of the specialty pharmaceutical company's stock worth $76,690,000 after purchasing an additional 309,966 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Supernus Pharmaceuticals by 26.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,685,122 shares of the specialty pharmaceutical company's stock valued at $45,077,000 after buying an additional 351,900 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Piper Sandler reissued a "neutral" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals in a report on Monday, January 6th. They set an "overweight" rating and a $57.00 target price on the stock. Finally, Cowen reissued a "buy" rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN traded down $0.44 on Thursday, hitting $37.87. The company's stock had a trading volume of 312,022 shares, compared to its average volume of 368,282. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $39.37. The company has a market capitalization of $2.09 billion, a PE ratio of 35.39 and a beta of 0.90. The company has a 50-day simple moving average of $36.62 and a 200 day simple moving average of $33.54.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.25. The business had revenue of $175.70 million during the quarter, compared to analyst estimates of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals's revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.29) earnings per share. On average, equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 earnings per share for the current fiscal year.

Insider Activity at Supernus Pharmaceuticals

In related news, CEO Jack A. Khattar sold 125,000 shares of the firm's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the transaction, the chief executive officer now directly owns 926,172 shares of the company's stock, valued at approximately $33,971,988.96. This trade represents a 11.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Frank Mottola sold 15,000 shares of the company's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the sale, the senior vice president now directly owns 8,200 shares of the company's stock, valued at approximately $303,236. This represents a 64.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 154,213 shares of company stock valued at $5,660,180 over the last 90 days. 9.30% of the stock is owned by insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.